TL;DR: In April 2026 the FDA removed 12 peptides from its Category 2 “significant safety risk” compounding list, but that did not make them compoundable. A Pharmacy Compounding Advisory Committee (PCAC) meeting on 23–24 July 2026 reviewed seven of them for the 503A bulks list, with FDA briefing documents proposing they not be added. None is FDA-approved.
The 2026 US peptide news cycle produced two headlines that are easy to misread. First, the FDA took a dozen popular peptides off a restrictive “do not compound” category. Second, an advisory committee met to weigh whether some of those same peptides should be formally authorized for pharmacy compounding. Read carelessly, this looks like a fast track to legitimacy. Read carefully, it is a procedural update that leaves every one of these substances unapproved and outside routine compounding.
This article walks through what actually changed, what the July 2026 PCAC meeting did and did not decide, and how the EU’s separate chemicals framework sits alongside all of it. It is a research-education reference, not legal or medical advice, and it follows our strict research-use-only posture throughout. For the broader legal map see our regulatory status and legal status overviews.
What Actually Changed in April 2026
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may only compound from a bulk drug substance if that substance meets one of three conditions: it is the subject of a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the FDA’s 503A bulks list. Substances that have been nominated but not yet evaluated sit in an interim scheme sorted into Category 1 (eligible for enforcement discretion while under review) and Category 2 (nominated substances the FDA has flagged as raising significant safety concerns).
In mid-April 2026 the FDA announced it was removing 12 peptide bulk substances from Category 2. The commonly reported list includes BPC-157, KPV, TB-500, MOTS-c, DSIP (emideltide), Epitalon, Semax, LL-37, DiHexa, PEG-MGF, injectable GHK-Cu, and Melanotan II. The change was tied to the FDA’s effective date of 23 April 2026.
Here is the crucial point that most headlines buried: removal from Category 2 does not make a substance compoundable. These peptides did not move to Category 1, and they are not covered by the interim enforcement-discretion policy. They simply left the “flagged as concerning” bucket while remaining ineligible for 503A compounding until, and unless, they are formally added to the bulks list through rulemaking. In practical terms, their legal footing for compounding was essentially unchanged.
The 23–24 July 2026 PCAC Meeting
The next procedural step is the Pharmacy Compounding Advisory Committee, the expert panel the FDA convenes to advise on bulks-list additions. PCAC met on 23–24 July 2026 at the FDA’s White Oak campus to consider whether seven of the de-listed peptides should be added to the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, DSIP (emideltide), Semax, and Epitalon. Each was considered in both free-base and acetate-salt forms.
Ahead of the meeting the FDA published briefing documents for each substance. For all seven, the agency’s proposed position was the same: do not add them to the 503A bulks list. The FDA’s stated reasoning generally centered on thin human safety data, limited or absent well-controlled clinical efficacy evidence, and uncertainty about physicochemical characterization and appropriate routes of administration. For some peptides the briefing materials noted the agency lacked adequate information to conclude the substance would not be harmful when administered to humans.
It is important to be precise about what a PCAC vote is worth. The committee is advisory: a favorable recommendation would only initiate FDA rulemaking to add a substance, and the agency is not bound to follow the committee. An unfavorable position, consistent with the briefing documents, makes near-term addition to the bulks list unlikely. Either way, as of this update none of these seven peptides is FDA-approved, and none is authorized for routine 503A compounding.
- 1
23 Apr 2026
FDA removes 12 peptides from Category 2 — a de-listing, not a green light.
- 2
23–24 Jul 2026
PCAC reviews 7 of them for the 503A bulks list; FDA briefing docs propose not adding any.
- 3
Rulemaking (if any)
A favorable vote would only initiate rulemaking — the agency is not bound to follow.
- 4
Status today
None FDA-approved; none authorized for routine 503A compounding.
Where the 12 Peptides Stand After July 2026
| Peptide | Removed from Category 2 (Apr 2026) | Reviewed by PCAC (Jul 2026) | FDA-approved drug? |
|---|---|---|---|
| BPC-157 | Yes | Yes | No |
| KPV | Yes | Yes | No |
| TB-500 | Yes | Yes | No |
| MOTS-c | Yes | Yes | No |
| DSIP (emideltide) | Yes | Yes | No |
| Semax | Yes | Yes | No |
| Epitalon | Yes | Yes | No |
| LL-37 | Yes | Not in first batch | No |
| DiHexa | Yes | Not in first batch | No |
| PEG-MGF | Yes | Not in first batch | No |
| GHK-Cu (injectable) | Yes | Not in first batch | No |
| Melanotan II | Yes | Not in first batch | No |
The takeaway from the table: a de-listing plus an advisory review does not equal approval. The regulatory status of every substance here remains “unapproved.”
What the Research Shows
Understanding why the FDA briefing documents were cautious requires looking honestly at the evidence base, which is overwhelmingly preclinical.
BPC-157 is the most-studied of the group. A 2025 literature and patent review in Pharmaceuticals catalogued broad “pleiotropic” activity across tissue-injury, inflammatory bowel disease, and CNS models, while stressing that it is not approved by any major regulator due to the absence of comprehensive human trials. A 2025 systematic review in the HSS Journal found 36 studies on musculoskeletal use — 35 preclinical and a single small human case series — underscoring how little controlled human data exists. A 2026 Pharmaceutics analysis went further, framing BPC-157’s core problem as a disconnect between extensive animal research, unresolved formulation and pharmacokinetic questions, and ongoing non-regulated use. You can read our deeper profile on the BPC-157 10mg research page.
KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone, has a genuinely interesting mechanistic literature: a 2008 Gastroenterology study demonstrated PepT1-mediated uptake and reduced intestinal inflammation in rodent colitis models. But this is animal and cell-culture pharmacology, not human clinical efficacy. That gap is exactly why the FDA flagged missing human safety information. See our KPV 5mg research page for the mechanistic detail.
For Semax (an ACTH(4-10)-derived heptapeptide studied for neurotrophic and BDNF-related effects) and Epitalon (a pineal tetrapeptide studied for telomerase and aging endpoints), a 2026 Frontiers in Aging review situates them within gerontology research while making clear the human evidence is limited and often from small or older studies. TB-500, MOTS-c, and DSIP are similarly characterized by mechanistic and animal work rather than robust, replicated human trials.
The honest summary across all seven: promising or at least plausible preclinical signals, but a thin and often low-quality human evidence base, no completed pivotal trials, and no regulatory approval. That is the scientific reality the compounding debate sits on top of.
The EU Picture: A Separate Chemicals Framework
None of the US 503A machinery applies in the European Union, which runs two parallel and quite different regimes. The first is the chemicals regime — the REACH Regulation (EC No 1907/2006) and the CLP Regulation (EC No 1272/2008) — under which a synthetic peptide sold strictly as a laboratory reagent is treated as a chemical substance, with Safety Data Sheets, Certificates of Analysis, and honest “research use only, not for human or veterinary use” labelling.
The second is the medicines regime under Directive 2001/83/EC, which captures a product as a medicinal product either by presentation (marketed with therapeutic claims) or by function. The moment a peptide is presented for treating disease or altering a bodily function, it typically becomes an unauthorised medicine, since none of these substances holds a marketing authorisation from the European Medicines Agency or a national agency. Notably, in 2026 the EMA also advanced guidance on the development and manufacture of synthetic peptides, reflecting growing regulatory attention to the category — though that guidance addresses manufacturing quality for authorised products, not a green light for research chemicals. Our EU-focused legal status guide covers the reagent-versus-medicine boundary in more depth.
The practical parallel between the two jurisdictions is simple. In the US, de-listing and advisory review did not make these peptides approved drugs. In the EU, the reagent framework only holds while presentation stays genuinely non-therapeutic; add a dosing chart or a healing claim and the same vial is reclassified as an unlicensed medicine.
Frequently Asked Questions
Are BPC-157 and the other peptides now legal to compound after April 2026?
No. Removal from Category 2 did not add them to the 503A bulks list or bring them under enforcement discretion. They remain ineligible for routine compounding unless the FDA formally adds them through rulemaking. As of this July 2026 update, none of the seven reviewed peptides is compoundable on that basis.
Did the July 2026 PCAC meeting approve any peptides?
No. PCAC is an advisory committee, not an approval body, and the FDA’s briefing documents proposed not adding any of the seven peptides. A favorable vote would only start a rulemaking process. Approval of a peptide as a drug is an entirely separate, far more demanding pathway that none of these substances has completed.
Does “removed from Category 2” mean the FDA decided these peptides are safe?
No. Category 2 removal was largely procedural and, in several cases, tied to withdrawn nominations rather than a safety clearance. The FDA’s July 2026 briefing documents actually cited limited human safety data and evidence gaps. De-listing changed a classification bucket, not the underlying evidence base.
Are these peptides FDA-approved for any human use?
No. None of the 12 de-listed peptides — including BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon — is an FDA-approved drug. The available evidence is predominantly preclinical (animal and cell-culture studies), with sparse and often low-quality human data and no completed pivotal clinical trials.
How does the EU regulate these peptides differently?
The EU has no 503A system. Peptides sold strictly as laboratory reagents fall under the REACH and CLP chemicals framework, while any therapeutic presentation triggers medicines law under Directive 2001/83/EC and, without a marketing authorisation, makes the product an unlicensed medicine. See our regulatory status page for the framework.
What is the difference between the 503A bulks list and enforcement discretion?
The 503A bulks list is a formal, rule-made roster of substances a pharmacy may compound from in bulk. Enforcement discretion is a temporary interim policy covering Category 1 nominated substances while they await evaluation. The July 2026 peptides were in neither favorable status after de-listing, leaving their compounding footing unchanged.
References
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185.
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA. Accessed 2026. Available at: fda.gov/media/94155/download.
- U.S. Food and Drug Administration. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 2026. FDA. Available at: fda.gov/media/193343/download.
- European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides. EMA/CHMP; 2026. Available at: ema.europa.eu.
- Regulation (EC) No 1907/2006 of the European Parliament and of the Council (REACH). Official Journal of the European Union; 2006.
- Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official Journal of the European Communities; 2001.
Research-use-only disclaimer: This article is an independent research-education reference for the EU audience and is provided for informational purposes only. It is not legal, medical, or regulatory advice. The peptides discussed are not approved drugs and are not authorized for human or veterinary use; nothing here should be read as a therapeutic claim or a dosing recommendation. Regulatory status can change — verify current FDA and EU/EMA guidance and consult qualified professionals before acting.